Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Light-Based scan spot preeclampsia before it strikes?

NCT ID NCT07106294

Diagnosis Sponsor: Heidelberg University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

Preeclampsia is a dangerous pregnancy condition marked by high blood pressure and damage to blood vessels, and it can threaten both mother and baby. This study tests whether hyperspectral imaging, a non-invasive scan that measures blood flow in the skin, can predict who will develop the condition. Researchers will follow about 1,430 pregnant women during routine ultrasound visits and compare imaging results with later preeclampsia diagnoses. The goal is to see if this technology can serve as an early warning tool.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hyperspectral imaging, a non-invasive, contact-free imaging technique that measures blood flow and tissue perfusion in the skin
What this could lead to
If it works, this could give doctors a simple, non-invasive way to predict preeclampsia early, allowing closer monitoring and timely care to protect mothers and babies.
What could go wrong
This is an observational study, not a treatment trial, so it will not change care directly. The imaging may not prove accurate enough for routine use, and results will need confirmation in future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,430 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

women scheduled for a routine ultrasound scan in first or second trimester

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * singleton pregnancies * age ≥ 18 years * patient's ability to provide consent * written informed consent * women scheduled for a routine ultrasound scan in first or second trimester Exclusion Criteria: * lack of consent * language barrier * severe fetal chromosomal/genetic/structural anomalies known at study enrollment * smoking in the last two hours before measurement * diagnosis of preeclampsia at study enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preeclampsia Preeclampsia (PE) risk

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Heidelberg University Hospital, Department of Gynecology and Obstetrics

    RECRUITING

    Heidelberg, 69120, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.